Latest News

ODAC Votes STARGLO Trial Not Applicable to US Patients With DLBCL
ODAC Votes STARGLO Trial Not Applicable to US Patients With DLBCL

May 20th 2025

In an 8 to 1 vote, the Oncologic Drug Advisory Committee determined that findings from the phase 3 STARGLO trial are not applicable to patients in the US with diffuse large B-cell lymphoma.

Bexobrutideg Gains FDA Orphan Drug Status in Waldenström Macroglobulinemia
Bexobrutideg Gains FDA Orphan Drug Status in Waldenström Macroglobulinemia

March 18th 2025

Extended SGX301 Treatment Shows Positive Results in Early-Stage CTCL
Extended SGX301 Treatment Shows Positive Results in Early-Stage CTCL

January 17th 2025

Glofitamab Plus Polatuzumab Shows Durable Results in R/R LBCL
Glofitamab Plus Polatuzumab Shows Durable Results in R/R LBCL

December 10th 2024

BOVen Regimen Appears Effective in High-Risk MCL
BOVen Regimen Appears Effective in High-Risk MCL

October 25th 2024

More News